Anticancer Activity of Some Ruthenium(III) Complexes with Quinolone Antibiotics: In Vitro Cytotoxicity, Cell Cycle Modulation, and Apoptosis-Inducing Properties in LoVo Colon Cancer Cell Line

Cisplatin is one of the most effective anticancer agents used to treat colon cancer, which is the third malignancy between the most common human cancers in the world, but the resistance developed represents an obstacle against the full success of chemotherapy. An emerging interest appeared in findin...

Full description

Saved in:
Bibliographic Details
Published inApplied sciences Vol. 11; no. 18; p. 8594
Main Authors Mihaila, Mirela, Hotnog, Camelia Mia, Bostan, Marinela, Munteanu, Alexandra Cristina, Vacaroiu, Ileana Adela, Brasoveanu, Lorelei Irina, Uivarosi, Valentina
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.09.2021
Subjects
Antibiotics
Antitumor activity
Apoptosis
cancer drug resistance
Cancer therapies
Cell cycle
Cell proliferation
Chemotherapy
Cisplatin
Colon
Colon cancer
Colorectal cancer
Cytotoxicity
Drug resistance
Flow cytometry
Ligands
Lysis
Malignancy
Medical research
Metal compounds
Ovarian cancer
quinolones
Ruthenium
ruthenium complexes
Online AccessGet full text

Cover

More Information
Summary:Cisplatin is one of the most effective anticancer agents used to treat colon cancer, which is the third malignancy between the most common human cancers in the world, but the resistance developed represents an obstacle against the full success of chemotherapy. An emerging interest appeared in finding other metallic compounds, such as ruthenium(III) complexes, for chemotherapeutic application in cancer. Our study focused on the anticancer activity of several ruthenium (Ru) complexes with quinolone antibiotics in colon tumor cell cultures. Real-time cell analysis and drug-mediated cytotoxicity tests monitored the inhibitory effects in the drug-treated LoVo colon cancer cells. Flow cytometry assays were performed to evaluate cell cycle phases distribution and apoptotic events. The obtained results showed dose-dependent increased levels of cell lysis and induction of apoptosis in LoVo cancer cells treated with the Ru(III) complexes. In addition, data showed a major decrease in cell proliferation, since the percentages of cells distributed in the S cell cycle phase diminished, and a G0/G1 cell arrest was observed. Therefore, our results strongly suggest that the newly synthesized Ru(III) complexes might play an important role in future chemotherapeutic approaches, since their activity is based on diminishing cell proliferation, induction of apoptosis, and modulation of cell cycle phases.
ISSN:2076-3417
2076-3417
DOI:10.3390/app11188594